GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Short Percentage of Float

FSD Pharma (FSD Pharma) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of FSD Pharma's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, FSD Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FSD Pharma's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, FSD Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where FSD Pharma's Short Percentage of Float falls into.


FSD Pharma (FSD Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Short Percentage of Float
Comparable Companies
TSXV:DB TSX:CWEB TSX:MDP TSXV:ZYUS XCNQ:MMEN XCNQ:CXXI XCNQ:GRIN TSX:AVNT XCNQ:ACRG.A.U XCNQ:GDNS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
0K9:Germany HUGE:Canada
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
Website
https://www.fsdpharma.com
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.